Format

Send to

Choose Destination
Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26937. Epub 2017 Dec 29.

Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.

Author information

1
Murdoch Children's Research Institute, Melbourne, Australia.
2
Children's Cancer Centre, The Royal Children's Hospital, Melbourne, Australia.
3
Department of Medicine, Melbourne University, Melbourne, Australia.

Abstract

Many paediatric patients with cancer experience significant chemotherapy side effects. Predisposition to drug reactions is governed by single nucleotide polymorphisms (SNPs). We performed a systematic review of the literature from 2006 through 2016. Outcomes of interest included patient characteristics, cancer type drug of interest, genes investigated, toxicity identified and genetic polymorphisms implicated. The primary toxicities studied were neurotoxicity cardiotoxicity, osteonecrosis, and thromboembolism and hypersensitivity reactions. The retrieved studies were grouped according to toxicity reported and SNP associations. This review highlights the discoveries to date in pharmacogenomics and paediatric oncology along with highlighting some of the important limitations in the area.

KEYWORDS:

adverse drug reactions; genome wide association studies; paediatric oncology; pharmacogenomics; single-nucleotide polymorphisms

PMID:
29286579
DOI:
10.1002/pbc.26937
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center